Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations
Open Access
- 25 November 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (12) , 1514
Abstract
Background/Objectives: Gabapentin has variable pharmacokinetics (PK), which contributes to difficulty in dosing and increased risk of adverse events. The objective of this study was to leverage gabapentin concentrations from therapeutic drug monitoring (TDM) to develop a population PK (popPK) model and characterize significant covariates that impact gabapentin PK. Methods: Data were retrospectively collected from 82 hospitalized adult patients with TDM gabapentin concentrations. Renal function indicators (i.e., estimated glomerular filtration rate, creatinine clearance, acute kidney injury), body weight parameters (i.e., actual body weight, ideal body weight, adjusted body weight, lean body weight, body mass index, obesity status), fasting plasma glucose levels, and diagnosis of type 2 diabetes were tested as potential covariates. A popPK model was developed in MONOLIX (2020R1, Lixoft, France). Results: A one-compartment model best described gabapentin PK with first-order absorption, dose-dependent bioavailability, first-order elimination, and no lag time. Population parameter estimates for the volume of distribution (Vd), and clearance (Cl) were 44.61 L, and 5.73 L/h, respectively. Serum creatinine was a significant covariate on Cl. Conclusions: The popPK model highlights the importance of renal function in the interindividual variability of gabapentin PK and suggests that diabetes and body weight parameters have no impact on gabapentin PK. Moreover, our study supports the utility of leveraging data obtained from clinical TDM for popPK model development.Keywords
This publication has 33 references indexed in Scilit:
- Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosingCPT: Pharmacometrics & Systems Pharmacology, 2023
- Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1Journal of Pharmacokinetics and Pharmacodynamics, 2017
- Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysisThe Lancet Neurology, 2015
- Gabapentin for chronic neuropathic pain and fibromyalgia in adults2014
- Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of DrugsClinical Pharmacokinetics, 2012
- Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgiaThe American Journal of Geriatric Pharmacotherapy, 2004
- Population pharmacokinetics of gabapentin in infants and childrenEpilepsy Research, 2001
- Inter- and intra-subject variability in gabapentin absorption and absolute bioavailabilityEpilepsy Research, 2000
- Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsyEpilepsy Research, 1998
- Pharmacokinetics of gabapentin in subjects with various degrees of renal functionClinical Pharmacology & Therapeutics, 1994